Angiocrine Bioscience (United States)
- Research works
- 39 ▲ 114% vs 2013–17
- Citations
- 397 10.2 per fractional work
- Top-10% rate
- 2.4% record average 16.5%
- Open access
- 15% world 28%
Not ranked overall: Angiocrine Bioscience (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at Angiocrine Bioscience (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Tumor Microenvironment, Cancer Therapy, Cell Death, Homologous Recombination, BRCA Mutation, Chemotherapy, PARP Inhibitors and Cancer.
- Innate Immunity
- Cancer Immunotherapy
- Precision Medicine
- Genomic Instability
- Breast Cancer
- PD-1 and PD-L1
- PARP Inhibitors
- Cancer
- Homologous Recombination
- Cancer Therapy
- Tumor Microenvironment
- Cell Death
- BRCA Mutation
- Chemotherapy
- Immune Checkpoint Blockade
- Targeted Therapy
- Gene Therapy
- Immunotherapy
- Tumor Regression
- Immunity
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 20 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 20 words, with their numbers
- Tumor Microenvironment3▲ 28×3 topics
- Cancer Therapy2▲ 21×3 topics
- Cell Death2▲ 45×2 topics
- Homologous Recombination2▲ 232×2 topics
- BRCA Mutation2▲ 395×1 topic
- Cancer2▲ 6.6×6 topics
- Chemotherapy2▲ 13×3 topics
- PARP Inhibitors2▲ 395×1 topic
- Immune Checkpoint Blockade2▲ 73×1 topic
- PD-1 and PD-L12▲ 73×1 topic
- Targeted Therapy2▲ 34×3 topics
- Breast Cancer2▲ 31×3 topics
- Gene Therapy1▲ 31×2 topics
- Genomic Instability1▲ 51×2 topics
- Immunotherapy1▲ 8.2×2 topics
- Precision Medicine1▲ 12×3 topics
- Tumor Regression1▲ 54×2 topics
- Cancer Immunotherapy1▲ 33×2 topics
- Immunity1▲ 12×2 topics
- Innate Immunity1▲ 15×2 topics
Which research topics does Angiocrine Bioscience (United States) publish most on?
By volume in 2022–2025: PARP inhibition in cancer therapy, Cancer Immunotherapy and Biomarkers, Cancer Research and Treatments and Cancer Genomics and Diagnostics.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 PARP inhibition in cancer therapy Oncology 2 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 3 Cancer Research and Treatments Biotechnology 1 works
- 4 Cancer Genomics and Diagnostics Cancer Research 1 works
- 5 HER2/EGFR in Cancer Research Oncology 1 works
- 6 Cancer Cells and Metastasis Oncology 1 works
- 7 Colorectal Cancer Treatments and Studies Oncology 1 works
- 8 Immunotherapy and Immune Responses Immunology 1 works
- 9 Cancer, Hypoxia, and Metabolism Cancer Research 1 works
- 10 Acute Myeloid Leukemia Research Hematology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Angiocrine Bioscience (United States)'s research output changed?
Output in 2018–2022 was 114% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in San Diego
- University of California San Diego
- San Diego State University
- Scripps Research Institute
- University of San Diego
- University of California San Diego Medical Center
- General Atomics (United States)
- Scripps Health
- Naval Medical Center San Diego
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.